Search for content, post, videos

Photocure presents positive data


Norwegian Photocure has announced new data from a prospective multicenter ongoing registry study that shows Blue Light Cystoscopy (BLC) with Cysview increases detection rates of flat, more aggressive non-muscle invasive bladder cancer lesions (carcinoma in situ (CIS)) as well papillary lesions over white light cystoscopy (WLC) alone.

The data from the prospective registry, real life, study including 175 patients, was presented at the American Urological Association (AUA) annual meeting in San Diego, CA, May 6-10, 2016.

The Blue Light Cystoscopy with Cysview Registry was established to study the use of BLC with Cysview in clinical practice in the US in different patient types. The data presented at AUA included an analysis of 175 patients at three major US urology and cancer centers between April 2014 and October 2015. A total of 548 separate lesions were identified from 220 BLC procedures. The detection rate (sensitivity) of WLC, BLC and the combination of WLC/ BLC for any malignant lesion was 73%, 91% and 98% respectively. The addition of BL to standard WLC increased the detection rate by 12% in any papillary lesions and 46% for CIS.


“This data further reinforces the critical role BLC with Cysview plays in advancing the care of bladder cancer patients,” says Siamak Daneshmand, MD, Associate Professor of Urology (Clinical Scholar) Director of Urologic Oncology, University of Southern California Institute of Urology and study investigator. “We know that BLC with Cysview has clear benefits over white light cystoscopy (WLC) alone in improving the detection and management of patients with non-muscle invasive bladder cancer (NMIBC).  That translates into reduction in disease progression and recurrence. Therefore, I believe that BLC with Cysview should be considered a valuable tool for urologists.”

“The registry will continue to add to the growing body of evidence of how BLC with Cysview can improve the detection and management of bladder cancer in various patient populations,” says Kjetil Hestdal, M.D., Ph.D., President and CEO, Photocure ASA.